

## IDO1

**Reactivity:** Human

**Tested applications:** WB

**Recommended Dilution:** WB 1:500 - 1:2000

**Calculated MW:** 45kDa

**Observed MW:** Refer to Figures

**Immunogen:**

Recombinant protein of human IDO1

**Storage Buffer:**

Store at -20. Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.

**Synonym:**

CD107B; IDO; INDO;

**Catalog #:** A1614

**Antibody Type:**

Polyclonal Antibody

**Species:** Rabbit

**Gene ID:** 3620

**Isotype:** IgG

**Swiss Prot:** P14902

**Purity:** Affinity purification

For research use only.

**Background:**

INDO/IDO1/indoleamine 2,3-dioxygenase (IDO) is an IFN--inducible enzyme that catalyzes the rate-limiting step of tryptophan degradation (1). IDO is upregulated in many tumors and in dendritic cells in tumor-draining lymph nodes. Elevated tryptophan catabolism in these cells leads to tryptophan starvation of T cells, limiting T cell proliferation and activation (2). Therefore, IDO is considered an immunosuppressive molecule, and research studies have shown that upregulation of IDO is a mechanism of cancer immune evasion (3). The gastrointestinal stromal tumor drug, imatinib, was found to act, in part, by reducing IDO expression, resulting in increased CD8+ T cell activation and induction of apoptosis in regulatory T cells (4). In addition to its enzymatic activity, IDO was recently shown to have signaling capability through an immunoreceptor tyrosine-based inhibitory motif (ITIM) that is phosphorylated by Fyn in response to TGF-. This leads to recruitment of SHP-1 and activation of the noncanonical NF-B pathway (5).

*To place an order, please [Click HERE](#).*